Follow-The-Filings

Security

AMRX

Amneal Pharmaceuticals Inc. · COM STK CL A

Equity holders as of 2026 Q1 (each manager’s latest book)

12 owners 2 new max 0.0% (D. E. Shaw & Co., Inc.)

grid → activity →
owners 12
max % 0.0%
tracked value $291M
qoq N 2 A 2 R 6

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
D. E. Shaw & Co., Inc. 2026 Q1 0.0% Reduce -0.01 pp 1,719,954 $21M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit -0.01 pp 301,028 $4M hist
Renaissance Technologies LLC 2026 Q1 0.0% Add +0.01 pp 276,637 $3M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Reduce 0.00 pp 17,907,815 $226M hist
Norges Bank 2025 Q4 stale 0.0% Exit 0.00 pp 889,500 $11M hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% Reduce 0.00 pp 864,792 $11M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Reduce -0.01 pp 577,419 $7M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Reduce -0.02 pp 369,733 $5M hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Reduce -0.01 pp 79,123 $983 hist
Steve Cohen - Point72 Asset Management, L.P. 2026 Q1 0.0% New 0.0% 78,105 $971 hist
Natixis Advisors, LLC 2026 Q1 0.0% New 0.0% 69,701 $866 hist
Joel Greenblatt - Gotham Asset Management, LLC 2026 Q1 0.0% Add 0.00 pp 22,308 $277 hist

12 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.39B $2.79B $3.02B
Gross profit $820.56M $1.02B $1.11B
Gross margin * 34.3% 36.5% 36.9%
Net income -$79.26M — $72.06M
Net margin * -3.3% — 2.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.38B $1.59B $1.91B
Total non-current assets * $2.09B $1.91B $1.77B
Total assets $3.47B $3.5B $3.68B
Total current liabilities $846.6M $1.13B $881.63M
Total non-current liabilities $2.56B $2.42B $2.79B
Total equity $19.78M -$109.27M -$70.79M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $345.58M $295.1M $339.99M
Cash from investing -$69.19M -$63M -$112.26M
Cash from financing -$212.57M -$211.79M -$31.53M
Net change in cash $63.88M $19.31M $194.52M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders